Polar Capital
VC Fund
London, United Kingdom
Polar Capital is a specialist investment management company offering professional and institutional investors a range of geographical and sector funds.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Polar Capital invests in
Stages Polar Capital invests in
Countries Polar Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gavin Rochussen
|
|||
Nick Martin
|
|||
|
John Mansell
|
|||
|
Tim Woolley
|
|||
Investment Focus
Industry
- Biotechnology 6 (55%)
- Pharmaceutical 4 (36%)
- Therapeutics 3 (27%)
- Banking 2 (18%)
- FinTech 2 (18%)
Stage
- Post-IPO Equity 7 (64%)
- Series A 1 (9%)
- Series D 1 (9%)
- Funding Round 1 (9%)
Country
- United Kingdom 4 (36%)
- United States 3 (27%)
- France 2 (18%)
- Sweden 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Gavin Rochussen
CEO
|
CEO | Total investments: 0 | Find email | |
|
Nick Martin
Fund Manager
|
Fund Manager | Total investments: 0 | Find email | |
|
John Mansell
CFO
|
CFO | Total investments: 0 | Find email | |
|
Tim Woolley
Co-Founder
|
Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MedinCell
|
MedinCell is an injectable slow-release drug specialist company. | $55.7M / Post-IPO Equity / Mar 05, 2026 | |
Hansa Biopharma
|
Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases. They concentrate on creating novel, life-saving and life-changing treatments that can meet the critical, unmet medical needs of individuals with uncommon immunological disorders. To target pathogenic ordisease-causing antibodies, they developed its proprietary antibody-cleaving enzyme technology platform. The company's diverse therapeutic pipeline has the potential to address significant unmet medical needs in transplantation, autoimmune diseases, gene therapy, and oncology indications. | $71M / Post-IPO Equity / Oct 02, 2025 | |
|
MedinCell
|
MedinCell is an injectable slow-release drug specialist company. | $44.7M / Post-IPO Equity / Feb 19, 2025 | |
Valneva
|
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $67.8M / Post-IPO Equity / Sep 13, 2024 | |
Spyre Therapeutics
|
Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies with the potential to revolutionize the treatment of inflammatory bowel disease (IBD). | $180M / Post-IPO Equity / Dec 07, 2023 | |
New Level Work
|
BetterManager provides leadership coaching and development programs for managers. They provide a proven, tech-enabled solution that has worked for some of the largest, most successful organizations out there. Founded in 2017, the firm has its headquarters in San Francisco, California, United States. | $16M / Series A / Nov 18, 2022 | |
Moneybox
|
Moneybox is a user-friendly app designed to help individuals save, invest, and manage pensions with ease. The app allows users to save specifically for their first home, making it an excellent choice for first-time buyers. The company focuses on helping individuals build wealth over time by offering a variety of financial services, including savingaccounts, investment products, and pensions, all accessible through a mobile app. | $45.9M / Series D / Apr 04, 2022 | |
Verona Pharma
|
Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough. | $200M / Post-IPO Equity / Jul 17, 2020 | |
Realm Therapeutics
|
Realm Therapeutics is a biopharmaceutical company passionately committed to leveraging its proprietary technologies to protect and improve the health of adults and children. The Company's drug development focus, utilizing its immunomodulatory formulations, is targeted initially on developing small molecule therapies in inflammatory diseaseswith potential application in dermatology and ophthalmology, and the potential for broad applicability across a number of other diseases. | $26M / Post-IPO Equity / Sep 22, 2017 | |
Plant Impact
|
Their products manage a plant’s natural responses to stress factors to build its resilience. This boost in strength helps the plant to flourish in good conditions but also when faced with increasingly common stresses such as heat, salinity, drought and the application of other chemicals.Their head office and primary research facility are at theRothamsted Centre for Research and Enterprise (RoCRE) in Harpenden, UK and they have additional offices in Brazil, USA and Argentina as well as colleagues based in Turkey and France. | $5.1M / Post-IPO Equity / Aug 23, 2017 | |
| See all 11 investments → | |||
Co-Investors
Perceptive Advisors
3 deals together
Abingworth
2 deals together
Access Biotechnology
2 deals together
Affinity Asset Advisors
2 deals together
Aisling Capital
2 deals together
Fairmount Funds Management
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Polar Capital invest in?
Polar Capital invests primarily in Biotechnology, Pharmaceutical and Therapeutics startups, most often at Post-IPO Equity and Series A stage. Most of the 11 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Polar Capital?
Public channels for Polar Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Polar Capital?
The team at Polar Capital includes Gavin Rochussen (CEO), Nick Martin (Fund Manager) and John Mansell (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
